The German group’s decision to switch focus to innate immunity had been on the cards since a deal with Roche last August.
In the wake of two phase III glioblastoma failures this month, from Abbvie and Bristol-Myers Squibb, hopes dim for another big readout from Tocagen.
The group’s Braftovi/Mektovi combo shows the potential of a targeted approach in colorectal cancer, so where is the competition?
First-look data on Abbott’s tricuspid-focused MitraClip follow-on device are promising, but can TriClip emulate its predecessor’s success?
Peloton Therapeutics’ approach to fighting kidney tumours has apparently convinced Merck & Co, which is to pay $1.05bn for the company on the back of relatively…
Three years after being merged with QLT the Aegerion business is to be sold out of bankruptcy protection.
The group is desperately playing up mirvetuximab, but its future rests with a pair of earlier-stage projects.
Two closely-watched liquid biopsy developers are to present data on their respective solid tumour blood tests.
As Meiragtx wows investors with its gene therapy for a cause of blindness, continuing lack of clarity around Gensight’s GS010 prompts more questions than answers.